Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E27.46 EPS (ttm)2.78 Insider Own0.10% Shs Outstand2.53B Perf Week-1.01%
Market Cap193.09B Forward P/E10.44 EPS next Y7.31 Insider Trans-9.96% Shs Float2.53B Perf Month2.07%
Income7.07B PEG3.16 EPS next Q1.64 Inst Own75.70% Short Float0.72% Perf Quarter-9.18%
Sales47.99B P/S4.02 EPS this Y-28.00% Inst Trans-0.37% Short Ratio1.49 Perf Half Y-4.66%
Book/sh10.01 P/B7.62 EPS next Y11.23% ROA7.90% Target Price96.10 Perf Year-6.51%
Cash/sh3.19 P/C23.95 EPS next 5Y8.70% ROE26.10% 52W Range71.71 - 87.80 Perf YTD-6.71%
Dividend2.60 P/FCF- EPS past 5Y12.20% ROI10.80% 52W High-13.09% Beta0.43
Dividend %3.41% Quick Ratio0.80 Sales past 5Y4.00% Gross Margin68.10% 52W Low6.41% ATR1.26
Employees74000 Current Ratio1.00 Sales Q/Q5.50% Oper. Margin16.50% RSI (14)50.36 Volatility1.37% 1.62%
OptionableYes Debt/Eq1.26 EPS Q/Q-188.00% Profit Margin14.70% Rel Volume0.64 Prev Close75.49
ShortableYes LT Debt/Eq1.00 EarningsApr 29 BMO Payout88.80% Avg Volume12.15M Price76.31
Recom1.90 SMA20-0.36% SMA500.93% SMA200-4.25% Volume7,793,947 Change1.09%
Apr-07-21Resumed RBC Capital Mkts Sector Perform $79
Nov-10-20Resumed Bernstein Outperform $95
Sep-29-20Initiated Berenberg Hold $88
Aug-03-20Upgrade Goldman Neutral → Buy $91 → $105
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Apr-09-21 01:39PM  
10:57AM  
Apr-08-21 08:31PM  
03:23PM  
01:23PM  
08:26AM  
06:45AM  
06:00AM  
Apr-07-21 02:05PM  
01:26PM  
11:01AM  
10:29AM  
08:54AM  
Apr-06-21 04:10PM  
02:43PM  
01:29PM  
Apr-05-21 02:06PM  
Apr-01-21 02:46PM  
02:07PM  
01:46PM  
08:30AM  
Mar-31-21 01:42PM  
11:59AM  
10:41AM  
10:24AM  
09:56AM  
Mar-30-21 03:15PM  
01:44PM  
01:27PM  
10:44AM  
09:51AM  
07:30AM  
06:45AM  
06:32AM  
Mar-29-21 05:45PM  
04:15PM  
02:05PM  
06:45AM  
Mar-26-21 02:14PM  
01:42PM  
11:45AM  
07:00AM  
Mar-25-21 06:15AM  
Mar-24-21 02:56PM  
01:34PM  
08:36AM  
06:45AM  
Mar-23-21 05:45PM  
02:53PM  
12:41PM  
09:41AM  
09:32AM  
06:45AM  
Mar-22-21 01:49PM  
12:03PM  
09:42AM  
09:28AM  
09:25AM  
Mar-19-21 06:45AM  
Mar-18-21 02:04PM  
10:30AM  
Mar-17-21 05:45PM  
04:27PM  
02:00PM  
01:48PM  
01:35PM  
12:22PM  
11:44AM  
08:34AM  
08:27AM  
07:00AM  
06:45AM  
Mar-16-21 02:43PM  
01:47PM  
01:30PM  
01:09PM  
12:45PM  
12:24PM  
11:23AM  
10:26AM  
06:45AM  
Mar-15-21 04:29PM  
02:04PM  
01:42PM  
12:14PM  
10:46AM  
10:19AM  
09:38AM  
06:47AM  
06:45AM  
06:43AM  
Mar-12-21 03:11PM  
01:57PM  
01:40PM  
09:43AM  
09:41AM  
09:39AM  
06:37AM  
Mar-11-21 05:45PM  
03:18PM  
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEONov 09Sale81.42280,00022,797,011411,546Nov 12 04:45 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise75.892,287173,56013,403Nov 03 04:48 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise75.894,574347,1217,624Nov 03 04:44 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise75.892,287173,56083,656Nov 03 04:55 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Option Exercise0.00251,2730422,329Oct 06 04:52 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Sale81.03251,27320,360,325171,056Oct 06 04:52 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 13Sale83.0110,380861,67667,373Aug 17 06:36 PM
Clyburn FrankEVP, Chief Commercial OfficerAug 05Option Exercise0.0018,876099,639Aug 06 04:53 PM
Clyburn FrankEVP, Chief Commercial OfficerAug 05Sale81.5518,8761,539,27480,763Aug 06 04:53 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJul 17Option Exercise0.0018,111062,862Jul 20 04:53 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJul 17Sale80.0036,2852,902,97626,577Jul 20 04:53 PM
BRUN LESLIE ADirectorMay 07Option Exercise0.005,00006,948May 07 04:48 PM
WEEKS WENDELL PDirectorMay 07Option Exercise0.005,00005,100May 07 04:50 PM
WEEKS WENDELL PDirectorMay 07Sale76.025,000380,104100May 07 04:50 PM
BRUN LESLIE ADirectorMay 07Sale75.465,000377,3001,948May 07 04:48 PM
Nally MichaelEVP, Chief Marketing OfficerMay 05Option Exercise76.862,345180,23712,054May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 05Option Exercise76.863,283252,33129,401May 06 05:15 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 05Option Exercise76.861,29099,1497,304May 06 05:16 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 05Option Exercise76.863,752288,37982,611May 06 05:17 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise77.671,904147,88479,797May 06 05:17 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise77.6769253,7486,252May 06 05:16 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise77.671,21294,13626,715May 06 05:15 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise77.675,772448,3119,489May 06 05:13 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise77.671,298100,81610,274May 06 05:14 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise77.6787567,96125,934May 05 04:48 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 03Option Exercise77.671,541119,6896,089May 05 04:42 PM